All In Biotech

Drug Trial Radar · NCT00070564

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,294 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

3,294

Actual

Start

Nov 2003

Primary completion

Jan 2015

Study completion Jan 2027

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Oct 7, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating resected breast cancer. PURPOSE: This randomized phase III trial is comparing 2 different regimens of combination chemotherapy to see how well they work in treating patients who have undergone surgery for stage I, stage II, or stage III breast cancer.

Conditions

  • Breast Cancer

Interventions

  • pegfilgrastimBiological

    Given IV

  • AC regimenDrug

    Given IV

  • cyclophosphamideDrug

    Given IV

  • doxorubicin hydrochlorideDrug

    Given IV

  • paclitaxelDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free SurvivalTime frame: every 6 months (annually for mammograms) for 5 years
  2. Overall SurvivalTime frame: Every 6 months for 5 years

Locations

542 sites in 3 countries. Site status is shown where the registry gives one.

  • Regional Medical Center

    Anniston, Alabama

  • UAB Comprehensive Cancer Center

    Birmingham, Alabama

  • Providence Cancer Center at Providence Hospital

    Mobile, Alabama

  • Providence Cancer Center

    Anchorage, Alaska

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona

  • Arizona Cancer Center at University of Arizona Health Sciences Center

    Tucson, Arizona

  • Hembree Mercy Cancer Center at St. Edward Mercy Medical Center

    Fort Smith, Arkansas

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Alta Bates Summit Comprehensive Cancer Center

    Berkeley, California

  • Peninsula Medical Center

    Burlingame, California

  • East Bay Radiation Oncology Center

    Castro Valley, California

  • Valley Medical Oncology Consultants - Castro Valley

    Castro Valley, California

  • Valley Medical Oncology

    Fremont, California

  • California Cancer Center - Woodward Park Office

    Fresno, California

  • Todd Cancer Institute at Long Beach Memorial Medical Center

    Long Beach, California

  • USC/Norris Comprehensive Cancer Center and Hospital

    Los Angeles, California

  • Contra Costa Regional Medical Center

    Martinez, California

  • Tibotec Therapeutics - Division of Ortho Biotech Products, LP

    Marysville, California

  • Memorial Medical Center

    Modesto, California

  • El Camino Hospital Cancer Center

    Mountain View, California

  • Sutter Health - Western Division Cancer Research Group

    Novato, California

  • Highland General Hospital

    Oakland, California

  • Alta Bates Summit Medical Center - Summit Campus

    Oakland, California

  • Bay Area Breast Surgeons, Incorporated

    Oakland, California

  • CCOP - Bay Area Tumor Institute

    Oakland, California

  • Larry G Strieff MD Medical Corporation

    Oakland, California

  • Tom K Lee, Incorporated

    Oakland, California

  • St. Joseph Hospital Regional Cancer Center - Orange

    Orange, California

  • Desert Regional Medical Center Comprehensive Cancer Center

    Palm Springs, California

  • Valley Medical Oncology Consultants - Pleasanton

    Pleasanton, California

  • Sutter Cancer Center at Roseville Medical Center

    Roseville, California

  • Sutter Cancer Center

    Sacramento, California

  • University of California Davis Cancer Center

    Sacramento, California

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • California Pacific Medical Center - California Campus

    San Francisco, California

  • Doctors Medical Center - San Pablo Campus

    San Pablo, California

  • Sutter Solano Medical Center

    Vallejo, California

  • San Luis Valley Regional Medical Center

    Alamosa, Colorado

  • University of Colorado Cancer Center at UC Health Sciences Center

    Aurora, Colorado

  • Memorial Hospital Cancer Center - Colorado Springs

    Colorado Springs, Colorado

Showing 40 of 542 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.